Calendrier des promotions Aura Biosciences, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Aura Biosciences, Inc.
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology. It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial. The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.Paramètres de base
IPO date
2021-10-29
ISIN
US05153U1079
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
Nom | Signification | Grade |
P/S | 0 | 0 |
P/BV | 2.69 | 6 |
P/E | 0 | 0 |
Efficacité
Nom | Signification | Grade |
ROA | -39.73 | 0 |
ROE | -46.01 | 0 |
ROIC | 0 | 0 |
Dividendes
Nom | Signification | Grade |
Rendement en dividendes | 0 | 0 |
DSI | 0 | 0 |
Croissance moyenne du dividende | 0 | 0 |
Devoir
Nom | Signification | Grade |
Debt/EBITDA | -0.2193 | 10 |
Debt/Ratio | 0.1028 | 10 |
Debt/Equity | 0.2009 | 10 |
Impulsion de croissance
Nom | Signification | Grade |
Rentabilité Revenue, % | 0 | 0 |
Rentabilité Ebitda, % | 299.93 | 10 |
Rentabilité EPS, % | 53.56 | 7 |
paper.price.prices
Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
common.calendar.number_days.1 | 6.42 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
common.calendar.number_days.7d | 6.97 $ | 0 $ | 0 $ | -7.89 % | 0 % | 0 % |
common.calendar.number_days.30d | 5.89 $ | 6.42 $ | 6.42 $ | +9 % | 0 % | 0 % |
common.calendar.number_days.90d | 5.3 $ | 4.9 $ | 6.97 $ | +21.13 % | 0 % | 0 % |
common.calendar.number_days.180d | 8.01 $ | 4.9 $ | 8.21 $ | -19.85 % | 0 % | 0 % |
common.calendar.number_days.1y | 7.73 $ | 4.9 $ | 11.74 $ | -16.95 % | 0 % | 0 % |
common.calendar.number_days.3y | 13.25 $ | 4.9 $ | 20.34 $ | -51.55 % | 0 % | 0 % |
common.calendar.number_days.5y | 4.9 $ | 4.9 $ | 24.89 $ | +131.02 % | 0 % | 0 % |
common.calendar.number_days.10y | 4.9 $ | 4.9 $ | 24.89 $ | +131.02 % | 0 % | 0 % |
common.calendar.number_days.ytd | 7.85 $ | 4.9 $ | 8.45 $ | -18.22 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
Superviseur | Titre d'emploi | Paiement | Année de naissance |
Dr. Elisabet de los Pinos Ph.D. | Founder, CEO, President & Director | 895.16k | 1974 (51 année) |
Ms. Julie B. Feder | Chief Financial Officer | 604.2k | 1971 (54 année) |
Dr. Mark Plavsic D.V.M., Ph.D. | Chief Technology Officer | N/A | 1961 (64 année) |
Mr. Patrick Nealon | Senior Vice President of Clinical Development Operations | N/A | |
Dr. Anthony Daniels M.D. | Therapeutic Area Head of Ocular Oncology | N/A | |
Dr. Richard Mountfield Ph.D. | Senior Vice President of Regulatory Affairs & Quality | N/A | |
Mr. Conor Kilroy | General Counsel & Secretary | N/A | 1982 (43 année) |
Dr. Jill J. Hopkins M.D. | Chief Medical Officer & President of Research and Development | N/A | 1965 (60 années) |
Informations sur l'entreprise
Adresse: United States, Boston. MA, 80 Guest Street - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.aurabiosciences.com
Site web: https://www.aurabiosciences.com